DEA Marijuana Hypocrisy Exposed: MMJ Legal Drug Blocked While Cartels Thrive in Marijuana Legal States
'The DEA is creating a regulatory paradox where science is stifled and illegal activity is tolerated. Thomas Prevoznik, one unelected bureaucrat should not have the power to derail federally authorized drug development,' said Duane Boise, CEO of MMJ International Holdings.
WASHINGTON, DC / ACCESS Newswire / May 18, 2025 / As the Drug Enforcement Administration (DEA) releases its 2025 National Drug Threat Assessment, a stunning contradiction emerges: while the DEA points fingers at states that have legalized marijuana for allegedly aiding transnational cartels, it continues to obstruct MMJ International Holdings and its subsidiaries - MMJBioPharma Cultivation and MMJ BioPharma Labs from lawfully developing cannabis based pharmaceutical drugs under full federal compliance.
For seven years, MMJ BioPharma has adhered strictly to federal statutes. It has received two Investigational New Drug (IND) applications from the U.S. Food and Drug Administration (FDA) and been awarded Orphan Drug Designation for its treatment of Huntington's disease. It has passed DEA security inspections and holds a DEA Schedule I Analytical Lab Registration. Yet, the DEA refuses to grant the necessary Schedule I Bulk Manufacturing Registration required for growing pharmaceutical grade cannabis for clinical trials, stonewalling innovation and delaying potential life-saving treatments.
Meanwhile, in its own report, the DEA claims that legal cannabis states are being exploited by Asian Transnational Criminal Organizations (TSOs), which operate under 'state-level business registrations' and ignore plant limits, production quotas, and licensing laws. The report claims these groups exploit inconsistencies in state regulations to shield illicit operations from federal enforcement.
Yet ironically, the DEA's continued blockade against legitimate federal drug developers like MMJ BioPharma is pushing innovation and pharmaceutical investment offshore. MMJ has openly criticized the agency's delays as 'a violation of law, science, and democracy.'
DEA Federal Hypocrisy on Full Display
DEA Acting Administrator Derek Maltz, who has called cannabis a 'gateway drug,' maintains the agency's hardline stance against MMJ's drug development despite its legal compliance and scientific rigor. Meanwhile, the agency paradoxically admits that the marijuana smuggled across state lines is primarily destined for non-legal states-a tacit admission that prohibition itself sustains the illicit market.
This undermines the DEA's narrative that legal states are the core problem. Instead, the report validates what advocates have long argued: that prohibition breeds black-market activity, while federal obstruction stalls medical progress.
Unelected Bureaucrats Holding Back Science
Thomas Prevoznik, DEA Deputy Assistant Administrator, has been directly implicated in MMJ's years-long delay. Legal filings and correspondence point to his central role in repeatedly stalling the company's application without justification. Despite the DOJ's withdrawal of support for unconstitutional ALJ procedures, DEA attorneys like Aarathi Haig continue to advance flawed legal defenses that conflict with DOJ policy and Supreme Court precedent.
'One unelected bureaucrat should not have the power to derail federally authorized drug development,' said Duane Boise, CEO of MMJ International Holdings. 'The DEA is creating a regulatory paradox where science is stifled and illegal activity is tolerated.'
Public Health Versus DEA Policy Posturing
Patients suffering from progressive diseases like Multiple Sclerosis and Huntington's continue to wait as DEA leadership prioritizes outdated drug war narratives over FDA-approved research. This obstructionism occurs while the agency allows illicit products grown in so-called 'legal' states to flood into black markets across the country.
The irony is lost on no one: the DEA has become both the gatekeeper and the roadblock to cannabis reform, impeding law-abiding researchers while blaming states for consequences rooted in federal dysfunction.
The Need for Congressional and Executive Action
The call for reform is now urgent. Congressional oversight must investigate the DEA's Diversion Control Division, its treatment of MMJ BioPharma, and its failure to execute consistent, science-based policies. President Trump's incoming DEA nominee Terrance Cole has promised to prioritize rescheduling marijuana but has yet to provide a definitive stance.
If the United States is serious about revitalizing its pharmaceutical industry and leading in medical cannabis innovation, agencies like the DEA must be held accountable. Otherwise, the message is clear: follow the law, and you'll be blocked. Break it, and you'll be blamed-but only after your profits are made.
MMJ BioPharma's legal struggle represents more than one company's battle; it symbolizes a national crossroads between science and stagnation, between integrity and institutional decay. The time for excuses is over.
The time for accountability is now.
MMJ is represented by attorney Megan Sheehan.
CONTACT:
Madison Hisey
[email protected]
203-231-85832
SOURCE: MMJ International Holdings
press release
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Forbes
28 minutes ago
- Forbes
No Pipeline, No Progress: Meeting The Demand For Advanced Degrees
As demand for master's and doctoral degrees surges, too few programs exist to support the students most often excluded—despite their potential. The United States stands at a crossroads. While innovation, competitiveness, and global leadership increasingly depend on highly educated workers, access to graduate education remains deeply unequal and underfunded. Over 60% of business and government leaders hold graduate degrees—with more than half in business and nearly a third in law. A 2020 report by Brint and colleagues found that 61% of top media figures and 78% of think tank and foundation leaders also held advanced degrees. In many leadership roles, graduate education is no longer a competitive advantage—it's a requirement. Demand is rising. A 2024 report from Georgetown University's Center on Education and the Workforce projects that nearly 1 in 5 jobs will soon require an advanced degree. Among 'good jobs'—those offering middle-class wages of $43,000 or more—1 in 4 will demand graduate credentials. Yet access to graduate education remains deeply inequitable. Madeline Brighouse Glueck finds that parental education still shapes graduate enrollment, especially in high-investment, high-return programs like law, medicine, and PhDs. In medicine alone, over 75% of students come from the top two income quintiles. Even academically qualified first-generation and low-income students are often left behind. While families with financial and social capital can navigate elite admissions and cover soaring costs, others are shut out. The only federally funded graduate pipeline program is the McNair Scholars Program, which supports first-generation, low-income, and underrepresented undergraduates seeking PhDs. This program—and others like Upward Bound—are now at risk of being defunded. As the federal government grows increasingly hostile toward identity-based programs in higher education, the burden of promoting equitable access is falling to the private sector and nonprofit organizations. Yet only a handful of national nonprofits directly focus on this issue: These organizations are doing powerful work—but their combined reach can only serve a fraction of the students who deserve access. To meet the moment, coordinated investments are needed—not just in graduate preparation, but also in affordability, mentorship, and long-term support: Graduate education is not a luxury—it is a national imperative. If we want to lead in science, health, law, and business—and if we believe in opportunity—we must invest in the people who will lead those fields. Let's ensure that talent, not zip code or family background, determines who has a seat at the table. Change can't wait. The time to invest is now. —--------- Help us widen the pipeline. Support Leadership Brainery in creating equitable pathways to graduate education. Donate today!
Motor Trend
30 minutes ago
- Motor Trend
The Cheapest Pickup Trucks You Can Buy in 2025 Aren't All Small
Almost across the board, pickup truck prices are creeping upward. Most of this is due to inflation (and more recently, tariffs), but formerly cheap trucks like the new generation Toyota Tacoma are going somewhat upmarket, while the price creep affecting the cheapest pickups like the Ford Maverick appears to be due to automakers capitalizing on unexpected success and, again, more recently, responding to tariffs. (The Maverick, like some other trucks on this list, is assembled outside of the U.S., which raises price pressure compared to home built options.) For now, the cheapest work trucks you can buy can still be had for under $40,000, but you don't need us to tell you that the versions of the most common full-size trucks most consumers buy are in the $50,000 to $60,000 range. Of course, the base price isn't the only metric by which to measure a truck, but it's an important one. If you want to explore other ways pickup trucks stack up against each other, MotorTrend 's proprietary algorithm provides the ultimate source of automotive data by combining over 75 years of our own instrumented performance, comfort, and efficiency testing on more than 5,000 vehicles. That data is fused with decades of expertise from former heads of design, engineering, and our own car buying experience experts. Built by statisticians and honed by automotive experts, MotorTrend 's Ultimate Car Rankings will assist in finding your perfect vehicle. But, you came here for cheap trucks, and here they are, the cheapest trucks you can buy in 2025:
Fox News
33 minutes ago
- Fox News
WATCH LIVE: Unite for Veterans, Unite for America rally on the National Mall
All times eastern Making Money with Charles Payne FOX News Radio Live Channel Coverage WATCH LIVE: Unite for Veterans, Unite for America rally on the National Mall
